Targeting CDH17 in Cancer: When Blocking the Ligand Beats Blocking the Receptor?
- PMID: 29084915
- DOI: 10.1158/1078-0432.CCR-17-2823
Targeting CDH17 in Cancer: When Blocking the Ligand Beats Blocking the Receptor?
Abstract
Cadherin-17 (CDH17) has been implicated as protumorigenic for many years, but mechanisms have been unclear. A Spanish team has generated antibodies to an RGD motif in CDH17 that inhibits integrin α2β1 binding to CDH17 and thereby inhibits integrin activation, tumorigenesis, and metastasis. These reagents may have therapeutic potential. Clin Cancer Res; 24(2); 253-5. ©2017 AACRSee related article by Bartolomé et al., p. 433.
©2017 American Association for Cancer Research.
Comment on
-
Monoclonal Antibodies Directed against Cadherin RGD Exhibit Therapeutic Activity against Melanoma and Colorectal Cancer Metastasis.Clin Cancer Res. 2018 Jan 15;24(2):433-444. doi: 10.1158/1078-0432.CCR-17-1444. Epub 2017 Sep 15. Clin Cancer Res. 2018. PMID: 28916526
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources